MedPath

Clinical Trial News

Uninterrupted Imatinib Use Improves Outcomes in Advanced GIST

  • A clinical trial reveals that continuous imatinib therapy significantly improves outcomes for patients with advanced gastrointestinal stromal tumors (GIST).
  • Patients who discontinued imatinib experienced faster disease progression, shorter time to imatinib resistance, and decreased overall survival compared to those who continued treatment.
  • The findings support current guidelines recommending uninterrupted imatinib treatment for advanced GIST patients who can tolerate the therapy's side effects.
  • The study underscores the importance of long-term follow-up in cancer trials to understand the impact of treatment strategies on drug resistance and survival.

Triptans Outperform Newer Migraine Drugs in Efficacy, Meta-Analysis Shows

  • A comprehensive meta-analysis reveals that older triptan medications, like eletriptan, are more effective for acute migraine treatment than newer gepants.
  • The study suggests eletriptan, rizatriptan, sumatriptan, and zolmitriptan offer superior pain relief and sustained pain freedom compared to lasmiditan, rimegepant and ubrogepant.
  • Researchers recommend triptans as a first-line treatment for migraines, given their efficacy and lower cost, but note contraindications for patients with cardiovascular issues.
  • The analysis highlights the underutilization of triptans in migraine management, urging healthcare professionals to consider them as a preferred option.

Cabozantinib Fails to Show Overall Survival Benefit in Papillary Renal Cell Carcinoma

  • The SWOG 1500 phase II trial found no statistically significant overall survival benefit with cabozantinib compared to sunitinib in advanced papillary renal cell carcinoma.
  • Median overall survival was 21.5 months for cabozantinib versus 17.3 months for sunitinib, with a hazard ratio of 0.83 (95% CI: 0.51–1.36, P = .46).
  • Cabozantinib did show improved progression-free survival and objective response rate compared to sunitinib in the primary analysis.
  • The study underscores the need for novel therapeutic strategies to improve outcomes in patients with advanced papillary renal cell carcinoma.

CHIP and mCAs Linked to Increased Risk of Breast and Colorectal Cancer

  • Clonal hematopoiesis of indeterminate potential (CHIP) is associated with a higher risk of developing breast cancer, with a hazard ratio of 1.30 (95% CI, 1.03-1.64; P = .02).
  • CHIP is linked to an increased risk of death from colorectal cancer, showing a hazard ratio of 3.99 (95% CI, 2.41-6.62; P < .001) without adjusting for disease stage.
  • Mosaic chromosomal alterations (mCAs) with a cell fraction greater than 5% are associated with a higher risk of breast cancer and death from colon cancer.
  • Further research into the biology of CHIP and mCAs could help stratify risk and reveal new therapeutic pathways in these cancers.

University of Hong Kong and Gleneagles Hospital Launch Clinical Trials Centre Focused on Oncology

  • The University of Hong Kong (HKU) and Gleneagles Hospital have opened a clinical trials centre to advance medical research and improve patient outcomes.
  • The centre will initially focus on oncology, conducting clinical trials for innovative drugs targeting various types of cancer, including colorectal and biliary tract cancers.
  • The collaboration aims to enhance research opportunities for patients in private hospitals and those from the Greater Bay Area, leveraging HKU's research expertise.
  • Gleneagles Hospital is pursuing accreditation as a nationally recognized clinical trial institute with China's National Medical Products Administration.

Aethlon Medical's Hemopurifier Receives Ethics Approval for Cancer Trial in India

  • Aethlon Medical's Hemopurifier has received ethics approval in India for a clinical trial targeting solid tumors resistant to anti-PD-1 therapies.
  • The trial will assess the safety, feasibility, and optimal dosage of Hemopurifier in patients with stable or progressive disease.
  • Hemopurifier aims to improve therapeutic response by removing tumor-produced extracellular vesicles from the bloodstream.
  • Aethlon anticipates beginning patient recruitment in Q4 2024, with the trial informing future oncology efficacy studies.

Anti-PD-1 Autoantibody Levels Predict Survival in Liver Cancer Patients Treated with Atezolizumab and Bevacizumab

  • Researchers found that higher levels of anti-PD-1 autoantibodies in blood serum correlate with lower survival rates in HCC patients undergoing Atezolizumab/Bevacizumab therapy.
  • The study suggests anti-PD-1 autoantibody levels could serve as a potential biomarker for predicting the efficacy of immune checkpoint inhibitors in HCC treatment.
  • This non-invasive method offers a way to identify patients less likely to respond to Atezo/Bev, potentially guiding more personalized treatment strategies.
  • The findings may pave the way for developing improved treatment regimens for liver cancer by predicting the efficacy of immune checkpoint inhibitors.

Bavarian Nordic's Mpox Vaccine Shows Promise in Adolescents, Securing EMA Approval

  • Bavarian Nordic's mpox vaccine, MVA-BN (Imvanex), has received EMA approval for use in adolescents aged 12-17, potentially expanding access in Africa.
  • A NIH-sponsored clinical trial demonstrated that adolescents showed non-inferior immune responses and similar safety profiles to adults after two doses.
  • The WHO has prequalified Imvanex for 'off-label' use, which may facilitate its use in infants, pregnant women, and immunocompromised individuals during outbreaks.
  • Bavarian Nordic is planning a Phase II clinical trial to assess the immunogenicity and safety of MVA-BN in children aged 2-12 years.

Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine

NCT05512949CompletedPhase 2
National Institute of Allergy and Infectious Diseases (NIAID)
Posted 9/9/2022

A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox

NCT05740982CompletedPhase 2
National Institute of Allergy and Infectious Diseases (NIAID)
Posted 3/22/2023

Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children from 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections

NCT06549530RecruitingPhase 2
Bavarian Nordic
Posted 10/21/2024

Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCT

NCT05745987Not Yet RecruitingPhase 4
McMaster University
Posted 9/1/2024

Nobias Therapeutics' NB-001 Shows Promise for 22q11.2 Deletion Syndrome

  • Nobias Therapeutics is developing NB-001, a first-in-class, non-stimulant activator of metabotropic glutamate receptors (mGluRs) for 22q11.2 Deletion Syndrome.
  • NB-001 is currently in Phase II clinical trials and is administered orally, targeting comorbid psychiatric conditions like anxiety, ADHD, and autism.
  • Early trial results indicate that NB-001 is safe and well-tolerated, offering a potential novel approach to managing 22q11.2 Deletion Syndrome.

Ignite Proteomics' RPPA Assay Drives Complete Response in HER2-Negative Breast Cancer

  • Ignite Proteomics launches a novel precision oncology assay using Reverse Phase Protein Array (RPPA) technology for breast cancer treatment decisions.
  • A case study demonstrated a complete response in a metastatic triple-negative breast cancer patient treated with trastuzumab deruxtecan (T-DXd) after RPPA identified HER2 expression.
  • The RPPA assay uniquely measures both the expression and activated protein drug target levels in breast tumors, improving targeted therapy effectiveness.
  • This clinically validated assay represents a significant advancement in personalized oncology care, potentially impacting patient outcomes.

Trending News

1

Vor Bio Secures Global Rights to Telitacicept in $4+ Billion Deal with RemeGen

2 days ago
2

Percheron Therapeutics Acquires Phase II-Ready Anti-VISTA Cancer Immunotherapy HMBD-002 in $290M Deal

2 days ago
3

Biogen Advances Salanersen to Phase 3 Studies for Spinal Muscular Atrophy After Promising Results

2 days ago
4

China Approves First Once-Daily Nebulized LAMA for COPD, Triggering $7.5M Milestone for Theravance

a day ago
5

Galderma Launches Phase II Trials of Nemolizumab for Systemic Sclerosis and Chronic Pruritus of Unknown Origin

3 days ago
6

ProFound Therapeutics Partners with Novartis in $775M Cardiovascular Drug Discovery Deal

a day ago
7

NHS Delivers First Brain-Infused Gene Therapy for Rare AADC Deficiency, Showing Promising Results in Three-Year-Old Patient

3 days ago
8

Lipocine Initiates Phase 3 Trial for Oral Brexanolone in Postpartum Depression

a day ago
9

UCB's Fenfluramine Achieves Positive Phase 3 Results in Ultra-Rare CDKL5 Deficiency Disorder

14 hours ago
10

FDA Approves Streamlined Access for Bristol Myers Squibb CAR T Cell Therapies

13 hours ago
Subscribe Icon

Daily Pharma Insights

Get curated, high-impact pharmaceutical news delivered to your inbox every morning.

  • Critical clinical trial updates & results
  • Regulatory approvals & strategic partnerships
  • Market access decisions & commercial developments
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy